Denali Capital Acquisition CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Semnur Pharmaceuticals, Inc. reported increased operating expenses and continued net losses in its Q2 2026 Form 10-Q, while advancing its SP-102 clinical trials.
Semnur Pharmaceuticals reported increased losses and negative cash flow for Q1 2026, raising substantial doubt about its going concern ability, while terminating two significant equity financing agreements.
Semnur Pharmaceuticals, Inc. reported significant operating losses and negative cash flows for Q3 2025, following its business combination and facing delays in anticipated capital raises.
Denali Capital Acquisition Corp. reports significant financial distress, including a going concern warning and Nasdaq delisting, as it pursues a merger with Semnur Pharmaceuticals.
Denali Capital Acquisition Corp. reports a net loss for the first quarter of 2025 and is addressing its Nasdaq delisting while pursuing a business combination with Semnur Pharmaceuticals.
Denali Capital Acquisition Corp. reported its financial results for the quarter ended September 30, 2024, while also detailing its ongoing efforts to secure a business combination and maintain its Nasdaq listing.
Denali Capital Acquisition Corp. reported a net income of $713,242 for the first six months of 2024, while navigating the complexities of finding a suitable business combination target.
Denali Capital Acquisition Corp. announced a net income of $264,330 for the first quarter of 2024, primarily driven by investment income, while continuing efforts to finalize its business combination with Longevity Biomedical, Inc.